A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
Clinical trial NCT06131372 · COMPLETED
Trial details
- NCT number
- NCT06131372
- Sponsor
- Novo Nordisk A/S
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-01
- Primary completion
- 2025-09-24
- Enrollment
- 626
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.